<?xml version='1.0' encoding='utf-8'?>
<document id="17414929"><sentence text="Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137."><entity charOffset="20-33" id="DDI-PubMed.17414929.s1.e0" text="emtricitabine" /><entity charOffset="35-44" id="DDI-PubMed.17414929.s1.e1" text="tenofovir" /><entity charOffset="50-57" id="DDI-PubMed.17414929.s1.e2" text="GS-9137" /><entity charOffset="88-101" id="DDI-PubMed.17414929.s1.e3" text="emtricitabine" /><entity charOffset="102-131" id="DDI-PubMed.17414929.s1.e4" text="tenofovir disoproxil fumarate" /><entity charOffset="136-145" id="DDI-PubMed.17414929.s1.e5" text="ritonavir" /><entity charOffset="154-161" id="DDI-PubMed.17414929.s1.e6" text="GS-9137" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e0" e2="DDI-PubMed.17414929.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e0" e2="DDI-PubMed.17414929.s1.e1" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e0" e2="DDI-PubMed.17414929.s1.e2" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e0" e2="DDI-PubMed.17414929.s1.e3" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e0" e2="DDI-PubMed.17414929.s1.e4" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e0" e2="DDI-PubMed.17414929.s1.e5" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e0" e2="DDI-PubMed.17414929.s1.e6" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e1" e2="DDI-PubMed.17414929.s1.e1" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e1" e2="DDI-PubMed.17414929.s1.e2" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e1" e2="DDI-PubMed.17414929.s1.e3" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e1" e2="DDI-PubMed.17414929.s1.e4" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e1" e2="DDI-PubMed.17414929.s1.e5" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e1" e2="DDI-PubMed.17414929.s1.e6" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e2" e2="DDI-PubMed.17414929.s1.e2" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e2" e2="DDI-PubMed.17414929.s1.e3" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e2" e2="DDI-PubMed.17414929.s1.e4" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e2" e2="DDI-PubMed.17414929.s1.e5" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e2" e2="DDI-PubMed.17414929.s1.e6" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e3" e2="DDI-PubMed.17414929.s1.e3" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e3" e2="DDI-PubMed.17414929.s1.e4" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e3" e2="DDI-PubMed.17414929.s1.e5" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e3" e2="DDI-PubMed.17414929.s1.e6" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e4" e2="DDI-PubMed.17414929.s1.e4" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e4" e2="DDI-PubMed.17414929.s1.e5" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e4" e2="DDI-PubMed.17414929.s1.e6" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e5" e2="DDI-PubMed.17414929.s1.e5" /><pair ddi="false" e1="DDI-PubMed.17414929.s1.e5" e2="DDI-PubMed.17414929.s1.e6" /></sentence><sentence text="To evaluate the potential for clinically relevant drug-drug interaction between emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and the ritonavir-boosted HIV integrase inhibitor GS-9137 (GS-9137/r)"><entity charOffset="80-93" id="DDI-PubMed.17414929.s2.e0" text="emtricitabine" /><entity charOffset="94-123" id="DDI-PubMed.17414929.s2.e1" text="tenofovir disoproxil fumarate" /><entity charOffset="125-128" id="DDI-PubMed.17414929.s2.e2" text="FTC" /><entity charOffset="129-132" id="DDI-PubMed.17414929.s2.e3" text="TDF" /><entity charOffset="142-151" id="DDI-PubMed.17414929.s2.e4" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e0" e2="DDI-PubMed.17414929.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e0" e2="DDI-PubMed.17414929.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e0" e2="DDI-PubMed.17414929.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e0" e2="DDI-PubMed.17414929.s2.e3" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e0" e2="DDI-PubMed.17414929.s2.e4" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e1" e2="DDI-PubMed.17414929.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e1" e2="DDI-PubMed.17414929.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e1" e2="DDI-PubMed.17414929.s2.e3" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e1" e2="DDI-PubMed.17414929.s2.e4" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e2" e2="DDI-PubMed.17414929.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e2" e2="DDI-PubMed.17414929.s2.e3" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e2" e2="DDI-PubMed.17414929.s2.e4" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e3" e2="DDI-PubMed.17414929.s2.e3" /><pair ddi="false" e1="DDI-PubMed.17414929.s2.e3" e2="DDI-PubMed.17414929.s2.e4" /></sentence><sentence text="" /><sentence text="Healthy adults were administered FTC/TDF (200/300 mg once daily) for 7 days, followed by randomization to the order of receiving GS-9137/r (50/100 mg once daily) and GS-9137/r plus FTC/TDF in a crossover fashion under fed conditions for 10 days"><entity charOffset="129-136" id="DDI-PubMed.17414929.s4.e0" text="GS-9137" /><entity charOffset="33-39" id="DDI-PubMed.17414929.s4.e1" text="FTC" /><entity charOffset="181-187" id="DDI-PubMed.17414929.s4.e2" text="FTC" /><entity charOffset="37-43" id="DDI-PubMed.17414929.s4.e3" text="TDF" /><entity charOffset="185-191" id="DDI-PubMed.17414929.s4.e4" text="TDF" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e1" e2="DDI-PubMed.17414929.s4.e1" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e1" e2="DDI-PubMed.17414929.s4.e3" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e1" e2="DDI-PubMed.17414929.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e1" e2="DDI-PubMed.17414929.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e1" e2="DDI-PubMed.17414929.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e3" e2="DDI-PubMed.17414929.s4.e3" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e3" e2="DDI-PubMed.17414929.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e3" e2="DDI-PubMed.17414929.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e3" e2="DDI-PubMed.17414929.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e0" e2="DDI-PubMed.17414929.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e0" e2="DDI-PubMed.17414929.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e0" e2="DDI-PubMed.17414929.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e2" e2="DDI-PubMed.17414929.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17414929.s4.e2" e2="DDI-PubMed.17414929.s4.e4" /></sentence><sentence text=" Pharmacokinetic (PK) blood draws were performed on days 7, 17, and 27" /><sentence text=" Lack of PK alteration for FTC, tenofovir (TFV), and GS-9137 was defined as a 90% confidence interval (CI) for the estimated ratio of geometric least squares means (coadministration/alone) between 70% and 143% for the primary PK parameters: maximum observed plasma concentration (Cmax), area under the plasma concentration-time curve over dosing interval (AUCtau), and trough concentration (Ctau)"><entity charOffset="32-41" id="DDI-PubMed.17414929.s6.e0" text="tenofovir" /><entity charOffset="27-35" id="DDI-PubMed.17414929.s6.e1" text="FTC" /><pair ddi="false" e1="DDI-PubMed.17414929.s6.e1" e2="DDI-PubMed.17414929.s6.e1" /><pair ddi="false" e1="DDI-PubMed.17414929.s6.e1" e2="DDI-PubMed.17414929.s6.e0" /></sentence><sentence text="" /><sentence text="Twenty-four of the 26 enrolled subjects completed the study with no serious adverse events or discontinuations attributable to adverse events" /><sentence text=" FTC, TFV, and GS-9137 PKs were unaffected during coadministration, with Cmax, AUCtau, and Ctau, meeting the protocol definition of equivalence and also the stricter bioequivalence criteria (90% CI: 80% to 125%)"><entity charOffset="1-3" id="DDI-PubMed.17414929.s9.e0" text="FTC" /></sentence><sentence text=" FTC and TFV PK parameters were comparable to historical values"><entity charOffset="1-3" id="DDI-PubMed.17414929.s10.e0" text="FTC" /></sentence><sentence text="" /><sentence text="There is no clinically relevant drug-drug interaction between FTC/TDF and GS-9137/r on their coadministration"><entity charOffset="62-64" id="DDI-PubMed.17414929.s12.e0" text="FTC" /><entity charOffset="66-68" id="DDI-PubMed.17414929.s12.e1" text="TDF" /><pair ddi="false" e1="DDI-PubMed.17414929.s12.e0" e2="DDI-PubMed.17414929.s12.e0" /><pair ddi="false" e1="DDI-PubMed.17414929.s12.e0" e2="DDI-PubMed.17414929.s12.e1" /></sentence><sentence text="" /></document>